← FDA DRUG APPROVALS

FDA ANDA · ANDA203367

PRAVASTATIN SODIUM

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA203367
TYPE
ANDA
ORIGINAL APPROVAL
2017-02-02
LATEST ACTION
2025-03-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 40MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 10MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 80MG · TABLET · ORAL
PRAVASTATIN SODIUMPrescription
PRAVASTATIN SODIUM 20MG · TABLET · ORAL

Approval history

2025-03-18Labeling · Supplement 9 · standardAP
2023-04-13Labeling · Supplement 7 · standardAP
2021-03-15Labeling · Supplement 5 · standardAP
2017-02-02UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →